Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2015 Sep 22;5:9889. doi: 10.1038/srep09889

Lack of association of the iNOS gene polymorphism with risk of cancer: a systematic review and Meta-Analysis

Jinghua Jiao 1,a, Jingyang Wu 2, Desheng Huang 3, Lei Liu 2,3,b
PMCID: PMC4585729  PMID: 26391304

Abstract

In order to investigate the association between the iNOS gene polymorphisms and susceptibility to cancer, a search of English papers was done using Pubmed, the Cochrane Library, Embase, ISI Web of Science, Google (scholar) database, and all Chinese reports were conducted using CBMDisc, Chongqing VIP database, and CNKI database. A total of eight studies were included in this meta-analysis including 1,920 cases and 2,373 controls. The results indicated that the polymorphisms in iNOS gene (C150T(Ser608 Leu) polymorphism and polymorphic (CCTTT)n repeats) had no association with cancer risk for all genetic models. This meta-analysis suggested that the polymorphisms in the iNOS gene were not associated with cancer risk.

It has been widely accepted that cancer was one of the important causes of dead all over the world, characterized by angiogenesis and inflamation1. To date, the etiology of cancer remains unknown and disease-modifying medical treatments are limited. Nevertheless, since the involvement of cytokines in cancer was hypothesized2, there were a lot of candidate genes approach in a case-control study of single nucleotide polymorphisms (SNPs) including inducible nitric oxide synthase (iNOS)3,4,5,6,7,8,9,10.

According to previous records, iNOS has played an important role in angiogenesis, stimulation of proliferation, and inhibition of apoptosis11. Previous research indicated that the iNOS gene might be involved in the development of cancer through disrupting carcinogenesis12. The chromosome allocation of iNOS is 17q11.2, which has a genomic size of 48 kb and encodes a protein of 131 kDa13. There were some known iNOS gene polymorphisms such as C150T (Ser608 Leu) polymorphisms and polymorphic (CCTTT)n repeats.

Thus far, previous studies concerning association between iNOS gene polymorphism and risk of cancer are limited and rather conflicting3,4,5,6,7,8,9,10. Because lack the evidence to provide a reliable conclusion in a single study, we conducted a meta-analysis on these eligible studies, to evaluate the strength relationship between the iNOS gene polymorphism and risk for cancer, which would have a much greater possibility of reaching reasonably strong conclusions.

Results

Study inclusion and characteristics

The process of the search was shown in Fig. 1. After a literature search, eight studies3,4,5,6,7,8,9,10(six studies3,4,6,7,8,9 with 1512 cases and 1942 controls for C150T (Ser608 Leu) polymorphism and two studies5,10 with 408 cases and 431 controls for polymorphic (CCTTT)n repeats) were included in this meta-analysis. The identified studies and their main characteristics were shown in Table 1 and Table 2. Genotype distribution of any polymorphism did not differ from HWE within control groups.

Figure 1.

Figure 1

Open in a new tab

Flow chart demonstrating those studies that were processed for inclusion in the meta-analysis.

Table 1. Characteristics of the Included Studies for Meta-analysis.

First Author PublicationYear Location Ethnicity Histology GenotypingMethod InosPolymorphism Cases(n) Controls(n) Cconflicts
Rafiei A3 2012 Iran Asian Gastric cancer PCR C150T(Ser608 Leu) 159 170 Significant association
Ferguson HR4 2008 Ireland Caucasian Esophageal adenocarcinoma TaqMan C150T(Ser608 Leu) 209 248 No significant association
Shen CH5 2007 Taiwan Asian Bladder carcinoma PCR (CCTTT)n 250 250 Significant association
Lee TS7 2007 Korea Asian Cervical cancer PCR C150T(Ser608 Leu) 176 172 No significant association
Li C9 2007 USA Caucasian Cutaneous melanoma PCR C150T(Ser608 Leu) 602 603 No significant association
Goto Y8 2006 Japan Asian Gastric cancer PCR-RFLP C150T 201 454 Significant association
Tatemichi M10 2005 Japan Asian Gastric cancer PCR (CCTTT)n 158 181 Significant association
Shen J6 2004 China Asian Gastric cancer PCR C150T(Ser608 Leu) 165 295 Significant association
Open in a new tab

PCR: polymerase chain reaction

Table 2. Distributions of the inducible nitric oxide synthase Genotype and Allele among Cases and Controls.

  Distribution of C150T(Ser608 Leu)genotypes Case/comtrol(n)
   Frequency of C150T(Ser608Leu)allelesCase/comtrol(n)
   Distribution of (CCTTT)nrepeats *genotypesCase/comtrol(n)
   Frequency of (CCTTT)n repeats*alleles Case/comtrol(n)
first author CC CT TT HWE forcontrol C T first author SS SL LL HWE forcontrol S L
Ferguson HR4 148/167 55/72 6/9 0.72 351/406 67/90 Shen CH5 45/56 113/110 87/79 0.14 203/222 287/268
Lee TS7 135/115 NA NA - NA NA Tatemichi M10 60/82 75/78 23/21 0.71 195/242 121/120
Li C9 404/393 184/187 14/23 0.89 992/973 212/233 - - - - - - -
Shen J6 108/189 33/49 2/8 0.06 249/427 37/65 - - - - - - -
Rafiei A3 89/92 59/72 11/6 0.07 237/256 81/84 - - - - - - -
Goto Y8 175/403 25/48 1/3 0.24 375/854 27/54 - - - - - - -
Open in a new tab

NA/-: Not applicable. HWE: Hardy-Weinberg equilibrium. *repeat numbers divided into two groups: S (9-11repeats) and L (12-18repeats).

Quantitative data synthesis

The results of analysis for different polymorphisms by Revman software was shown in Fig. 2 and Fig. 3. As shown in Table 3, the results indicated that there was no association between polymorphisms in the iNOS gene including C150T (Ser608 Leu) polymorphisms and polymorphic (CCTTT)n repeats and risk of cancer. In subgroup analysis for C150T (Ser608 Leu) polymorphism by ethnicity (OR = 1.04, 95% CI = 0.82-1.32 for T vs. C; OR = 1.10, 95% CI = 0.52-2.33 for TT vs. CC; OR = 1.13, 95% CI = 0.53-2.41 for TT vs. CT; OR = 1.14, 95% CI = 0.54-2.38 for recessive model; OR = 0.98; 95% CI = 0.77-1.25 for dominant model) among Asians. There was no significant publication bias according to funnel plot (Fig. 4) and Egger’s test (p = 0.65).

Figure 2.

Figure 2

Open in a new tab

a. Forest plot of the association between cancer and the C150T(Ser608 Leu) mutation (T vs C). b. Forest plot of the association between cancer and the C150T(Ser608 Leu) mutation (TT vs CC). c. Forest plot of the association between cancer and the C150T(Ser608 Leu) mutation (TT vs CT).

Figure 3.

Figure 3

Open in a new tab

a. Forest plot of the association between cancer and the C150T(Ser608 Leu) mutation (TT vs CT+CC). b. Forest plot of the association between cancer and the C150T(Ser608 Leu) mutation (CT+TT vs CC).

Table 3. Summary ORs and 95% CI of the C150T(Ser608 Leu) Polymorphism and the polymorphic (CCTTT)n repeats in the inducible nitric oxide synthase Gene and Cancer Risk.

Statistical models Genotype/Allele Numberof Study OR 95%CI I2% P Z P forZ test
C150T(Ser608 Leu)                
Allele Model T vs. C 5 0.94 0.81-1.08 0 0.83 0.88 0.38
Codominant model TT vs. CC 5 0.77 0.49-1.21 0 0.41 1.12 0.26
  TT vs. CT 5 0.82 0.52-1.30 22 0.28 0.84 0.4
Recessive model TT vs. CT+CC 5 0.79 0.51-1.24 12 0.34 1.01 0.31
Dominant model TT+CT vs. CC 6 0.93 0.80-1.09 0 0.89 0.87 0.39
Subgroup                
C150T(Ser608 Leu) in Asian                
Allele Model T vs. C 3 1.04 0.82-1.32 0 0.90 0.35 0.72
Codominant model TT vs. CC 3 1.10 0.52-2.33 0 0.29 0.24 0.81
  TT vs. CT 3 1.13 0.53-2.41 46 0.16 0.31 0.75
Recessive model TT vs. CT+CC 3 1.14 0.54-2.38 31 0.23 0.34 0.74
Dominant model TT+CT vs. CC 4 0.98 0.77-1.25 0 0.74 0.14 0.89
(CCTTT)n repeats*                
Allele Model L vs. S 2 1.20 0.99-1.46 0 0.75 1.83 0.07
Codominant model LL vs. SS 2 1.41 0.95-2.11 0 0.84 1.69 0.09
  LL vs. SL 2 1.09 0.77-1.54 0 0.88 0.49 0.63
Recessive model LL vs. SL+SS 2 1.19 0.86-1.65 0 0.76 1.07 0.29
Dominant model LL+SL vs. SS 2 1.33 0.98-1.82 0 0.93 1.83 0.07
Open in a new tab

OR: odds ratio; CI: confidence interval. *repeat numbers divided into two groups: S (9-11 repeats) and L (12-18 repeats).

Figure 4.

Figure 4

Open in a new tab

Funnel plot of studies conducted on the association between C150T(Ser608 Leu) mutation and cancer risk.

Sensitivity Analysis

In order to examine the influence of the individual data set to the pooled ORs, every single study was deleted each time. Sensitivity analysis indicated our results were statistically robust (data not shown).

Discussion

As a production of nitric oxide (NO), iNOS is produced during inflammation by macrophages14. Expression of iNOS in response to cytokines is one of the important sections for inflammatory reaction and relates to angiogenesis, suggesting its potential role in the process of carcinogens15. The polymorphism (C150T) in exon 16 of iNOS gene results in an amino acid substitute, Ser608 Leu. The iNOS Ser608 Leu allele (C > T polymorphism) leads an amino acid alteration in a regulatory domain of the enzyme16. Furthermore, a polymorphic pentanucleotide (CCTTT)n repeat probably 2.5 kilobase substream the transcription initiation site has been clarified to affect iNOS expression17. In our meta-analysis, the associations between these two polymorphisms in iNOS gene and risk of cancer were studied.

Except detection the expression of iNOS in vivo or in vitro with tumor18,19, there were some other researches in cancer patients that susceptibility to carcinogenesis may be correlated with the existence of particular alleles at the iNOS locus. However, the results are inconsistent and inconclusive due to limited sample size and different study methods. To the best of our knowledge, this is the first meta-analysis to evaluate iNOS gene polymorphism in development and growth of cancer. In order to acquire a more reliable and comprehensive evidence on both variants, we conducted this meta-analysis to evaluate the association between the polymorphism in iNOS gene and risk of cancer on the basis of data from eight studies. The results indicated that there was no significant association for iNOS gene polymorphism and risk of cancer. In addition, another iNOS gene (iNOS974) was studied in the relationship with cancer. However, there was no significant difference between iNOS974 polymorphism and cancer risk9.

Although we have not found a significant association between iNOS gene polymorphisms and cancer risk, some studies revealed that the risk of cancer is increasing among smoking or drinking individuals with polymorphism in iNOS gene5,6. In addition, studies also reported that iNOS gene polymorphism was associated with the risk of H pylori-related gastric cancer3,8. We could provide a hypothesis that there was an association between iNOS gene and risk of cancer combined with risk factors including lifestyle and H pylori infection. As the reason for heterogeneity (including different study methods and outcomes) among studies, we could not use meta-analysis to analyze the relationship between iNOS genes combined with those risk factors and cancer.

This meta-analysis has pooled the available data from the eligible studies, which has significantly increased the statistical power. Nevertheless, the results of the present meta-analysis should also be explained within the context of its limitations. First, cancer is a multi-factorial illness from complex interactions between environmental exposure and genetic factors. In this meta-analysis, we had insufficient data to conduct an evaluation of such interactions for the role of iNOS polymorphisms and factors in cancer development. Second, the number of current studies is relative limited. Thus, investigations involving large number of different races are necessary for a more reliable assessment on their associations. Third, our meta-analysis is based on unadjusted estimate because lacking of sufficient data. Forth, although we have made our best efforts to avoid all potential publications, it is likely that some are missed or displayed erroneously. Furthermore, we did not include studies published in language other than English or Chinese.

In conclusion, this meta-analysis revealed that the polymorphisms in iNOS gene could not be regarded as a strong genetic risk factor for cancer but it might be association with cancer combined with additional risk factors. In addition, this result should be interpreted cautiously. In order to better understand the potential etiology for cancer in human, large well-designed studies in the susceptibility of cancer evidence are needed to perform in future. It also will be necessary to combine genetic factors and other environmental risk factors.

Methods

Selection of eligible studies

Studies on the associations between iNOS gene polymorphisms and cancer were scrutinized by two reviewers (L.L. and J.H.J.) independently. We searched Pubmed, Embase, the Cochrane Library, ISI Web of Science, Google (scholar) database, Chinese Biological Medicine Disc (CBMDisc), China National Knowledge Infrastructure (CNKI), and Chongqing VIP database (Last search was updated on December 10, 2014) using the terms “inducible nitric oxide synthase or iNOS”, “cancer or tumor or carcinoma” and “polymorphism, variant or mutation”. Reference lists were checked and additional literatures were contacted by researchers. Authors of publications were contacted when results were unclear or when sufficient data were not reported. The search was performed without restriction on language, but we only included articles written in English or Chinese.

Selection Criteria

Studies were included if they fulfilled all of the following entry criteria: (1) it must be a case-control or cohort study design; (2) there were sufficient data for iNOS gene mutations with risk of cancer; (3) the genotype distribution in the controls of all studies should be in agreement with Hardy-Weinberg equilibrium (HWE); and (4) in the case of multiple publications from the same study group, the most complete and recent results were used.

Exclusion criteria

The exclusion criteria were defined as: (1) abstracts, reviews and studies on animal; (2) useless data reported, genotype number or frequency was not included; and (3) genotype distribution in the control population not consistent with HWE.

Data extraction

After studies selection, two investigators independently extracted data from each study with a standard form and entered into a database. When discrepancies were appeared, all investigators were recruited to evaluate the data. The following information was collected: First author, publication year, location, ethnicity, characteristics, sample sizes of patients and controls, genotype numbers.

The review and analysis were guided to conduct by the PRISMA statement for preferred reporting of systematic reviews and meta-analysis20.

Statistical analysis

Odds ratios (ORs) with 95% confidence intervals (CIs) for genotypes and alleles were used to assess the strength of association between iNOS gene polymorphisms and risk of cancer. The ORs were conducted for the allele contrast, codominant model, recessive model, and dominant model, respectively. Heterogeneity was examined with I2 statistic interpreted as the proportion of total variation contributed by between-study variation. If there was significant heterogeneity, the random effects model would be used to analyze the pooled ORs21,22. Otherwise, the pooled ORs were analyzed by the fixed effects model23. The potential publication bias was assessed with funnel plot and Egger’s test. An asymmetric plot suggests a possible publication bias and the P value of Egger’s test being considered representative of significant publication bias if it was less than 0.0524. All statistical tests were performed by RevMan software (version 5.0, Review Manager, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2010) and Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood Cliffs, I.N.J., USA). P value less than 0.05 for any test was considered to be statistically significant.

Additional Information

How to cite this article: Jiao, J. et al. Lack of association of the iNOS gene polymorphism with risk of cancer: a systematic review and Meta-Analysis. Sci. Rep. doi: 10.1038/srep09889 (2015).

Acknowledgments

Thanks to our English teacher Dr. Sharon Forsyth who is the Director of Biomedical Editing International in Australia to copyedite this article. Thanks to Xiaomei Wu, Ph.D, Professor of the Department of Clinical Epidemiology and Evidence Medicine in the First Affiliated Hospital of China Medical University.

Footnotes

Author Contributions J.H.J. and L.L. have contributed to the design of the study, analysis and interpretation of data and drafting a part of manuscript. J.H.J. and D.S.H. also took part in analyzing data, and drafting a part of manuscript. L.L. and J.H.J. investigated and collected data. L.L., J.H.J. and J.Y.W. carried out statistical analysis. L.L., J.H.J. and J.Y.W. prepared all figures and tables. All authors reviewed the manuscript.

References

  1. Hammam O. et al. A Possible Role for TNF-α in Coordinating Inflammation and Angiogenesis in Chronic Liver Disease and Hepatocellular Carcinoma. Gastrointest Cancer Res. 6, 107–114 (2013). [PMC free article] [PubMed] [Google Scholar]
  2. Li J. et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun. 1, 1–8 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Rafiei A. et al. Inducible nitric oxide synthetase genotype and Helicobacter pylori infection affect gastric cancer risk. World J Gastroenterol. 18, 4917–4924 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ferguson H. R. et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 17, 727–731 (2008). [DOI] [PubMed] [Google Scholar]
  5. Shen C. H. et al. Inducible nitric oxide synthase promoter polymorphism, cigarette smoking, and urothelial carcinoma risk. Urology 69, 1001–1006 (2007). [DOI] [PubMed] [Google Scholar]
  6. Shen J. et al. A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. World J Gastroenterol. 10, 3278–3283 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lee T. S. et al. Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci. 1095, 134–142 (2007). [DOI] [PubMed] [Google Scholar]
  8. Goto Y. et al. Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population. World J Gastroenterol. 12, 6361–6365 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Li C. et al. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer 109, 1570–1578 (2007). [DOI] [PubMed] [Google Scholar]
  10. Tatemichi M. et al. Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett. 217, 197–202 (2005). [DOI] [PubMed] [Google Scholar]
  11. Wang D., Mann J. R. & DuBois R. N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology, 128, 1445–61 (2005). [DOI] [PubMed] [Google Scholar]
  12. Lala P. K. & Chakraborty C. Role of nitricoxide in carcinogenesis and tumour progression. Lancet Oncol. 2, 149–156 (2001). [DOI] [PubMed] [Google Scholar]
  13. Marsden P. A. et al. Localization of the human gene for inducible nitric oxide synthase (NOS2) to chromosome 17q11.2-q12. Genomics 19, 183–185 (1994). [DOI] [PubMed] [Google Scholar]
  14. Felley C. P. et al. Oxidative stress in gastric mucosa of asymptomatic humans infected with Helicobacter pylori: effect of bacterial eradication. Helicobacter 7, 342–348 (2002). [DOI] [PubMed] [Google Scholar]
  15. Vallance P. & Collier J. Biology and clinical relevance of nitri coxide. Br Med J. 309, 453–457 (1994). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johannesen J. et al. Linkage of the human inducible nitric oxide synthase gene to type 1 diabetes. J Clin Endocrinol Metab. 86, 2792–2796 (2001). [DOI] [PubMed] [Google Scholar]
  17. Xu W. et al. Evolution of a homopurine homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene. 204, 165–170 (1997). [DOI] [PubMed] [Google Scholar]
  18. Brandão M. M., Soares E., Salles T. S. & Saad S. T. Expression of inducible nitric oxide synthase is increased in acute myeloid leukaemia. Acta Haematol. 106, 95–99 (2001). [DOI] [PubMed] [Google Scholar]
  19. Takahashi M., Mutoh M., Kawamori T., Sugimura T. & Wakabayashi K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21, 1319–1327 (2000). [PubMed] [Google Scholar]
  20. Moher D. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. DerSimonian R. & Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28, 105–114 (2007). [DOI] [PubMed] [Google Scholar]
  22. DerSimonian R. & Laird N. Meta-analysis in clinical trials. Control Clin Trials 7, 177–188 (1986). [DOI] [PubMed] [Google Scholar]
  23. Mantel N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22, 719–748 (1959). [PubMed] [Google Scholar]
  24. Egger M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES